{
    "clinical_study": {
        "@rank": "63947", 
        "arm_group": [
            {
                "arm_group_label": "Dose Escalation", 
                "arm_group_type": "Experimental", 
                "description": "Dose Escalation of MEDI0680 (AMP-514) and MEDI4736 in combination"
            }, 
            {
                "arm_group_label": "Dose Expansion", 
                "arm_group_type": "Experimental", 
                "description": "Dose Expansion at selected dose from escalation phase"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerability of MEDI0680 (AMP-514) given in combination with\n      MEDI4736."
        }, 
        "brief_title": "A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Malignancies", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be 18 years or older\n\n          -  Eastern Cooperative Oncology Group performance status of 0-1\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Concurrent enrollment in another clinical study, unless in follow-up period or it is\n             an observational study\n\n          -  Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer\n             treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118337", 
            "org_study_id": "D6020C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Dose Escalation", 
                    "Dose Expansion"
                ], 
                "description": "anti-PD-1", 
                "intervention_name": "MEDI0680 (AMP-514):  MEDI0680 and AMP-514 are interchangable nomenclature", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Dose Escalation", 
                    "Dose Expansion"
                ], 
                "description": "anti-PD-L1", 
                "intervention_name": "MEDI4736", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "advanced malignancies", 
        "lastchanged_date": "April 16, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies", 
        "other_outcome": [
            {
                "description": "To assess drug exposure and response to treatment", 
                "measure": "Serum sPD-L1 Levels", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drugs until 90 days after last dose of study drugs"
            }, 
            {
                "description": "To assess drug exposure and response to treatment", 
                "measure": "PD-1 expression/MEDI0680 (AMP-514) receptor occupancy", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drugs until end of study"
            }, 
            {
                "description": "To assess cell populations with drug exposure and response to treatment", 
                "measure": "Flow Cytometry levels", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drugs through the last dose of study drugs"
            }, 
            {
                "description": "to assess pre and post treatment levels with response to treatment with study drugs", 
                "measure": "Circulating Soluble Factor levels", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drugs until 90 days after last dose of study drugs"
            }, 
            {
                "description": "To determine the molecules and biomarkers present in the tumor microenvironment pre and post dose", 
                "measure": "Expression of biomarkers within the tumor microenvironment", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drugs until end of study"
            }, 
            {
                "description": "to determine changes in gene expression from baseline", 
                "measure": "miRNA/mRNA levels in the blood", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drugs through end of study"
            }, 
            {
                "description": "To determine the genetic profile of the tumor in relation to response or resistance", 
                "measure": "Biopsy specimen results", 
                "safety_issue": "No", 
                "time_frame": "From screening through end of study"
            }, 
            {
                "description": "Tumor response will be assessed by irRECIST", 
                "measure": "Tumor Response", 
                "safety_issue": "No", 
                "time_frame": "From screening through end of study"
            }, 
            {
                "description": "Assessed through questionnaires regarding quality of life, symptoms, pain, and health status", 
                "measure": "Patient Reported Outcomes", 
                "safety_issue": "No", 
                "time_frame": "From screening through end of study"
            }
        ], 
        "overall_contact": {
            "email": "ClinicalTrialEnquiries@Medimmune.com", 
            "last_name": "MedImmune Contact"
        }, 
        "overall_official": {
            "affiliation": "Sponsor GmbH", 
            "last_name": "Joyson Karakunnel, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determination of maximum tolerated dose (MTD) to be assessed by number of AEs and SAEs, laboratory evaluations, vital signs, physical examinations, and electrocardiogram results", 
            "measure": "Acceptable number of subjects with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "From first dose of study drugs until 90 days after the last dose of study drugs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118337"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured by OR, DC, DoR, PFS and OS", 
                "measure": "Antitumor activity of MEDI0680 (AMP-514) in combination with MEDI4736 in subjects with advanced malignancies", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drugs until end of study"
            }, 
            {
                "description": "Individual concentrations in serum including peak and trough concentration", 
                "measure": "Pharmacokinetics of MEDI0680 (AMP-514) and MEDI4736", 
                "safety_issue": "No", 
                "time_frame": "From first dose through 12 months after last dose of study drugs"
            }, 
            {
                "description": "Immunogenicity measured by presence of detectable ADAs", 
                "measure": "Immunogenicity of MEDI0680 (AMP-514) and MEDI4736", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drugs until 90 days after last dose of study drugs"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}